Lubiprostone neither decreases gastric and small-bowel transit time nor improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled study.
BACKGROUND
Lubiprostone, a selective activator of type 2 chloride channels, is approved for treatment of chronic idiopathic constipation and recently constipation-predominant irritable bowel syndrome. It has been suggested that lubiprostone has a prokinetic effect.


OBJECTIVE
This investigation was designed to evaluate lubiprostone as a preparation and propulsive agent for small-bowel capsule endoscopy. The PillCam Small Bowel capsule endoscopy system with the PillCam SB1 capsule and Rapid 5 software platform were used.


METHODS
The study was designed as a double-blind, placebo-controlled trial.


METHODS
Forty healthy adults.


METHODS
Gastric transit time (GTT), small-bowel transit time (SBTT), and adequacy of small-bowel cleansing preparation.


METHODS
The study subjects received 24 mug lubiprostone or placebo 30 minutes before PillCam capsule ingestion.


METHODS
Capsule endoscopy studies were read by 2 independent investigators unaware of the study medication received, and differences in interpretation were resolved by consensus. Anatomical landmarks were identified, and GTT and SBTT were calculated. Overall preparation quality assessment of the proximal, mid, and distal small bowel was determined by using a 4-step scale. The percentage of visualized bowel was determined by review of 10-minute video segments at 1-hour intervals after the capsule passed through the pylorus.


RESULTS
In the lubiprostone group (n = 20), 2 subjects did not pass the capsule through the pylorus in the 8-hour battery life of the capsule. An additional 3 capsules did not pass into the colon. In the placebo group (n = 20), all capsules passed into the small bowel, but 1 did not pass into the colon. The subjects in whom the capsule did not pass into the small bowel were excluded from the small-bowel analysis. In the subjects in whom the capsule did reach the colon, the SBTT could not be calculated and they were excluded from SBTT analysis. The mean GTT in the lubiprostone group was 126 minutes and 43 minutes in the placebo group (P = .0095). The mean SBTT in the lubiprostone group was 188 minutes and 219 minutes in the placebo group (P = .130). The overall preparation assessment of the small bowel was not statistically significant between the 2 groups in the proximal, mid, or distal small bowel (proximal, P = .119; mid, P = .118; distal, P = .121). There was no significant difference in lubiprostone compared with placebo in the percentage of visualized small bowel.


CONCLUSIONS
Some capsules did not leave the stomach or reach the cecum.


CONCLUSIONS
Lubiprostone produced a significant increase in GTT but did not result in a significant decrease in SBTT compared with placebo. The administration of lubiprostone before capsule ingestion did not result in improved overall preparation of the small bowel for capsule endoscopy or increase the percentage of visualized small bowel. (The trial was registered at www.clinicaltrials.gov, identifier NCT00746395.).
Hooks
S Bennett
SB
University of South Alabama College of Medicine, Mobile, Alabama 36693, USA.
Rutland
Travis J
TJ
Di Palma
Jack A
JA
D000328:Adult; D000527:Alprostadil / Q000008:administration & dosage / Q000031:analogs & derivatives*; D053704:Capsule Endoscopy / Q000379:methods*; D018118:Chloride Channels; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D005772:Gastrointestinal Transit / Q000187:drug effects*; D006801:Humans; D007421:Intestine, Small / Q000033:anatomy & histology / Q000187:drug effects* / Q000502:physiology; D000068238:Lubiprostone; D008297:Male; D012016:Reference Values; D012189:Retrospective Studies
D018118:Chloride Channels; D000068238:Lubiprostone; D000527:Alprostadil